Clinical trial uses combination therapy for certain types of non-Hodgkin lymphoma

lymphoma cells

Lymphoma tumor cells
Photo credit: NCI Visuals Online

Adults diagnosed with indolent or diffuse large B-cell lymphoma (DLBCL) may be eligible to participate in a new clinical trial at the NIH Clinical Center.

Non-Hodgkin lymphoma can be indolent or aggressive. Indolent lymphoma tends to grow and spread slowly and has few signs and symptoms while aggressive lymphoma grows and spreads quickly and has signs and symptoms that can be severe. DLBCL is the most common type of non-Hodgkin lymphoma. It grows quickly in the lymph nodes and often the spleen, liver, bone marrow or other organs are also affected. Mark Roschewski, M.D., of the Lymphoid Malignancies Branch is testing the safety of an experimental drug, Hu5F9-G4, with rituximab, a standard treatment. Hu5F9-G4 is an antibody that is designed to target and block a protein that is present on cancer cells and is used by those cells to protect themselves from your body’s immune system. Blocking the protein with Hu5F9-G4 may enable your body’s immune system to find and destroy the cancer cells.

The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care.  Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.  

For more information on CCR clinical trials click here and subscribe to have the latest CCR clinical trials sent directly to your inbox.

Summary Posted: Thu, 03/01/2018